Gefurulimab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-15 in 3mo
ESTIMATED |
READOUT
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With ACh
Phase 3 · Generalized Myasthenia Gravis, gMG |
Alexion Pharmaceuticals, Inc. | Gefurulimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|